Yr Athro James Walters

2026

• Fenner, E. et al. 2026. Analysis of rare coding variants in schizophrenia-associated genes and generalised cognition in the UK Biobank. Molecular Psychiatry 31 , pp.5104-5113. (10.1038/s41380-026-03601-8)
• Gergel, T. et al., 2026. A tool to evaluate the impact of lived experience involvement in research: the Brain and Genomics Hub Impact Log protocol. Wellcome Open Research 11 562. (10.12688/wellcomeopenres.27426.1)
• Das, U. et al., 2026. The association of schizophrenia polygenic scores with continuously-hospitalized, treatment-resistant schizophrenia. Molecular Psychiatry (10.1038/s41380-026-03806-x)
• Eisner, E. et al., 2026. Using passive sensing to predict psychosis relapse: an in-depth qualitative study exploring perspectives of people with psychosis. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 52 (4) sbaf126. (10.1093/schbul/sbaf126)
• Murtough, S. et al., 2026. ACKR1 /Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx). British Journal of Clinical Pharmacology 92 (7), pp.1977-1990. (10.1002/bcp.70576)
• Quinn, A. et al., 2026. Severe Mental Illness Longitudinal Evaluation (SMILE): protocol for establishing a cohort and bioresource for UK-based patients with psychosis. BMJ Open 16 (7) e116077. (10.1136/bmjopen-2025-116077)
• Rossi, F. et al., 2026. Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes. Nature Genetics 58 , pp.1559-1572. (10.1038/s41588-026-02646-3)
• Yao, K. et al., 2026. Integrating genome-wide and epigenome-wide associations for antipsychotic induced extrapyramidal side effects. Psychopharmacology 243 , pp.1631-1642. (10.1007/s00213-025-06912-w)
• Bladon, S. et al., 2026. Evaluating wearable devices for remote monitoring in psychosis: Pilot study nested within the CONNECT cohort study. JMIR Formative Research 10 e86049. (10.2196/86049)
• Godoi, D. C. , Walters, J. T. and Legge, S. E. 2026. Behavioural and genetic predictors of positive symptoms in psychotic disorders [Abstract]. European Psychiatry 69 (S1), pp.S177-S177. (10.1192/j.eurpsy.2026.10526)
• Ter Kuile, A. et al., 2026. Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder. Molecular Psychiatry (10.1038/s41380-026-03677-2)
• King, B. et al., 2026. Neurometabolites and antipsychotic response in psychosis. JAMA Psychiatry (10.1001/jamapsychiatry.2026.1674)
• Skelton, M. et al., 2026. Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry. Nature Human Behaviour 10 , pp.1594-1608. (10.1038/s41562-026-02476-7)
• Katzourou, I. K. et al. 2026. Neurodevelopmental copy-number variants increase risk of internalizing and cardiometabolic multimorbidity: Findings from the UK Biobank. American Journal of Human Genetics 113 (6), pp.1319-1329. (10.1016/j.ajhg.2026.02.021)
• Deakin, B. et al., 2026. Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences. Molecular Psychiatry 31 , pp.1983-1991. (10.1038/s41380-025-03337-x)
• Eisner, E. et al., 2026. Views of people with psychosis about algorithm-based relapse prediction and data sharing: qualitative study. Journal of Medical Internet Research 28 e86753. (10.2196/86753)
• Maina, J. G. et al., 2026. Psychiatric genetics research in Africa: challenges, opportunities and strategic insights from the Depression Genetics in Africa (DepGenAfrica) study. The British Journal of Psychiatry (10.1192/bjp.2026.10578)
• Lynham, A. J. et al. 2026. Acceptability of the Cardiff Online Cognitive Assessment for clinical screening of patients with psychosis: Protocol for a mixed methods study. JMIR Research Protocols 15 e84218. (10.2196/84218)
• Smart, S. E. et al. 2026. Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol. PLoS ONE 21 (2) e0340584. (10.1371/journal.pone.0340584)
• Ball, H. et al., 2026. Mental health professionals’ perspectives on digital remote monitoring in services for people with psychosis. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 52 (1) sbaf043. (10.1093/schbul/sbaf043)
• Murtough, S. et al., 2026. ACKR1 genetic testing should be offered before starting clozapine treatment. Nature Mental Health 4 , pp.30-41. (10.1038/s44220-025-00554-9)
• Kendall, K. M. et al. 2026. The relationship between schizophrenia polygenic scores, blood-based proteins and psychosis diagnosis in the UK Biobank. Schizophrenia 12 24. (10.1038/s41537-025-00725-8)
• Grotzinger, A. D. et al., 2026. Mapping the genetic landscape across 14 psychiatric disorders. Nature 649 , pp.406-415. (10.1038/s41586-025-09820-3)

2025

• Colbert, S. M. C. et al., 2025. Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group. Molecular Psychiatry 30 , pp.6144-6154. (10.1038/s41380-025-03271-y)
• Owen, M. J. et al. 2025. Genomics of schizophrenia, bipolar disorder and major depressive disorder. Nature Reviews Genetics 26 , pp.862-877. (10.1038/s41576-025-00843-0)
• Richards, A. L. et al. 2025. Effects of shared and nonshared schizophrenia and bipolar disorder alleles on cognition and educational attainment in the UK Biobank. Biological Society: Global Open Science 5 (6) 100601. (10.1016/j.bpsgos.2025.100601)
• Walters, J. , Willcocks, I. and Pardinas, A. 2025. Current Trends in Genetic Research [b. Genetic Research]. In: Albertson, D. N. et al., Research Methods in Mental Health: A Comprehensive Guide. Cambridge: Cambridge University Press. , pp.267-312. (10.1017/9781009028967.016)
• Howes, O. D. et al., 2025. Relapse in schizophrenia: a systematic review of criteria for clinical studies and international consensus guidelines to improve them. The American Journal of Psychiatry 182 (11), pp.969-983. (10.1176/appi.ajp.20241040)
• Smart, S. E. et al. 2025. The role of SLC39A8.p.( Ala391Thr ) in schizophrenia symptom severity and cognitive ability: cross‐sectional studies of schizophrenia and the general UK population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 198 (7), pp.135-146. (10.1002/ajmg.b.33037)
• Uffelmann, E. et al., 2025. Estimating disorder probability based on polygenic prediction using the BPC approach. Nature Communications 16 (1) 8443. (10.1038/s41467-025-62929-x)
• Cardno, A. G. et al., 2025. Associations between psychotic experience dimensions and polygenic liability to schizophrenia in a longitudinal birth cohort. BJPsych Open 11 (5) e197. (10.1192/bjo.2025.10825)
• Baune, B. T. et al., 2025. A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe. European Archives of Psychiatry and Clinical Neuroscience 275 , pp.1453-1464. (10.1007/s00406-024-01944-3)
• Skelton, M. et al., 2025. Genetic overlap between functional impairment and depression and anxiety symptom severity: Evidence from the GLAD Study. Psychological Medicine 55 e224. (10.1017/s0033291725101037)
• Chick, S. L. et al. 2025. Whole-exome sequencing analysis identifies risk genes for schizophrenia. Nature Communications 16 (1) 7102. (10.1038/s41467-025-62429-y)
• Kappel, D. et al. 2025. Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK. The Lancet Psychiatry 12 (6), pp.447-456. (10.1016/S2215-0366(25)00123-3)
• Koch, E. et al., 2025. Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data. The Lancet Psychiatry 12 (6), pp.457-468. (10.1016/S2215-0366(25)00061-6)
• Lock, S. K. et al. 2025. Antipsychotic and pharmacogenomic effects on cross-sectional symptom severity and cognitive ability in schizophrenia. EBioMedicine 116 105745. (10.1016/j.ebiom.2025.105745)
• Katzourou, I. et al. 2025. Contributions of common and rare genetic variation to different measures of mood and anxiety disorder in UK Biobank. BJPsych Open 11 (3) e97. (10.1192/bjo.2025.43)
• McNabb, C. B. et al. 2025. WAND: A multi-modal dataset integrating advanced MRI, MEG, and TMS for multi-scale brain analysis. Scientific Data 12 220. (10.1038/s41597-024-04154-7)
• Cardno, A. G. et al., 2025. Associations of psychotic symptom dimensions with clinical and developmental variables in twin and general clinical samples. The British Journal of Psychiatry 226 (1), pp.16-23. (10.1192/bjp.2024.129)

2024

• Woolway, G. E. et al., 2024. Assessing the validity of a self-reported clinical diagnosis of schizophrenia. Schizophrenia 10 (1) 99. (10.1038/s41537-024-00526-5)
• Koch, E. et al., 2024. How real-world data can facilitate the development of precision medicine treatment in psychiatry. Biological Psychiatry 96 (7), pp.543-551. (10.1016/j.biopsych.2024.01.001)
• Cameron, D. et al. 2024. Genetic implication of prenatal GABAergic and cholinergic neuron development in susceptibility to schizophrenia. Schizophrenia Bulletin Open 50 (5), pp.1171-1184. (10.1093/schbul/sbae083)
• Legge, S. E. et al. 2024. Genetic and phenotypic features of Schizophrenia in the UK Biobank. JAMA Psychiatry 81 , pp.681-690. (10.1001/jamapsychiatry.2024.0200)
• Trastulla, L. et al., 2024. Distinct genetic liability profiles define clinically relevant patient strata across common diseases. Nature Communications 15 5534. (10.1038/s41467-024-49338-2)
• Kendall, K. et al. 2024. The translation of psychiatric genetics findings to the clinic. Schizophrenia Research 267 , pp.470-472. (10.1016/j.schres.2023.10.024)
• Caseras, X. et al. 2024. Common risk alleles for schizophrenia within the major histocompatibility complex predict white matter microstructure. Translational Psychiatry 14 194. (10.1038/s41398-024-02910-2)
• Kappel, D. et al. 2024. Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia. European Neuropsychopharmacology 80 , pp.47-54. (10.1016/j.euroneuro.2023.12.007)
• Casetta, C. et al., 2024. CLEAR – clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings. BMC Psychiatry 24 (1) 122. (10.1186/s12888-023-05397-1)

2023

• Davies, H. L. et al., 2023. The network structure of mania symptoms differs between people with and without binge eating. Bipolar Disorders 25 (7), pp.592-607. (10.1111/bdi.13355)
• Griffiths, K. et al., 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260 , pp.152-159. (10.1016/j.schres.2023.08.020)
• Lee, S. C. et al., 2023. Trends in socioeconomic inequalities in incidence of severe mental illness – A population-based linkage study using primary and secondary care routinely collected data between 2000 and 2017. Schizophrenia Research 260 , pp.113-122. (10.1016/j.schres.2023.08.014)
• Lock, S. K. et al. 2023. Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count. Schizophrenia 9 74. (10.1038/s41537-023-00404-6)
• Palmer, E. R. et al., 2023. Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Trials 24 (1) 646. (10.1186/s13063-023-07499-3)
• Doherty, A. et al., 2023. Genome-wide association study meta-analysis of suicide attempt identifies twelve genome-wide significant loci and implicates genetic risks for specific health factors. The American Journal of Psychiatry 180 (10), pp.723-738. (10.1176/appi.ajp.21121266)
• Owen, M. et al. 2023. Genomic findings in schizophrenia and their implications. Molecular Psychiatry 28 , pp.3638-3647. (10.1038/s41380-023-02293-8)
• Lynham, A. , Jones, I. and Walters, J. 2023. Cardiff online cognitive assessment in a national sample: cross-sectional web-based study. Journal of Medical Internet Research 25 e46675. (10.2196/46675)
• Ollà, I. et al., 2023. Pathogenic mis-splicing of CPEB4 in schizophrenia. Biological Psychiatry 94 (4), pp.341-351. (10.1016/j.biopsych.2023.03.010)
• Maury, E. A. et al., 2023. Schizophrenia-associated somatic copy-number variants from 12,834 cases reveal recurrent NRXN1 and ABCB11 disruptions. Cell Genomics 3 (8) 100356. (10.1016/j.xgen.2023.100356)
• Fenn-Moltu, S. et al., 2023. The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaboration. Brain, Behavior, and Immunity 111 , pp.343-351. (10.1016/j.bbi.2023.05.005)
• Bright, S. J. et al., 2023. Sociodemographic, mental health, and physical health factors associated with participation within re-contactable mental health cohorts: an investigation of the GLAD Study. BMC Psychiatry 23 542. (10.1186/s12888-023-04890-x)
• Allardyce, J. et al. 2023. Specificity of polygenic signatures across symptom dimensions in bipolar disorder: an analysis of UK Bipolar Disorder Research Network data. The Lancet Psychiatry 10 (8), pp.623-631. (10.1016/S2215-0366(23)00186-4)
• Millgate, E. et al., 2023. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255 , pp.173-181. (10.1016/j.schres.2023.03.020)
• Johnson, E. C. et al., 2023. Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. Psychological Medicine 53 (4), pp.1196-1204. (10.1017/S003329172100266X)
• Lynham, A. J. et al. 2023. DRAGON-Data: A platform and protocol for integrating genomic and phenotypic data across large psychiatric cohorts. BJPsych Open 9 (2) e32. (10.1192/bjo.2022.636)
• Pardinas, A. F. et al. 2023. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. The Lancet Psychiatry 10 (3), pp.209-219. (10.1016/S2215-0366(23)00002-0)
• Rammos, A. et al. 2023. Family-based analysis of the contribution of rare and common genetic variants to school performance in schizophrenia. Molecular Psychiatry 28 , pp.2081-2087. (10.1038/s41380-023-02013-2)
• Liu, D. et al., 2023. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. Nature Genetics 55 , pp.369-376. (10.1038/s41588-023-01305-1)
• Davies, M. R. et al., 2023. Factors associated with anxiety disorder comorbidity. Journal of Affective Disorders 323 , pp.280-291. (10.1016/j.jad.2022.11.051)
• Kappel, D. B. et al. 2023. Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scores. Biological Psychiatry 93 , pp.149-156. (10.1016/j.biopsych.2022.07.014)

2022

• Pistis, G. et al., 2022. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry 27 , pp.5135-5143. (10.1038/s41380-022-01779-1)
• Smart, S. E. et al. 2022. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research 250 , pp.1-9. (10.1016/j.schres.2022.09.009)
• Rayner, C. et al., 2022. Patient characteristics associated with retrospectively self-reported treatment outcomes following psychological therapy for anxiety or depressive disorders - a cohort of GLAD study participants. BMC Psychiatry 22 (1) 719. (10.1186/s12888-022-04275-6)
• Woolway, G. et al. 2022. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophrenia Bulletin 48 (5), pp.967-980. (10.1093/schbul/sbac049)
• Bracher-Smith, M. et al. 2022. Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK Biobank. Schizophrenia Research 246 , pp.156-164. (10.1016/j.schres.2022.06.006)
• Richards, A. et al. 2022. Genetic liabilities differentiating bipolar disorder, schizophrenia and major depression and phenotypic heterogeneity in bipolar disorder. JAMA Psychiatry 79 (10), pp.1032-1039. (10.1001/jamapsychiatry.2022.2594)
• Creeth, H. D. J. et al. 2022. Ultrarare coding variants and cognitive function in schizophrenia. JAMA Psychiatry 79 (10), pp.963-970. (10.1001/jamapsychiatry.2022.2289)
• D’Ambrosio, E. et al., 2022. A polygenic score indexing a DRD2 -related co-expression network is associated with striatal dopamine function. Scientific Reports 12 (1) 12610. (10.1038/s41598-022-16442-6)
• Griffiths, K. et al., 2022. Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. Schizophrenia 8 (1) 60. (10.1038/s41537-022-00265-5)
• Palmer, D. et al., 2022. Exome sequencing in bipolar disorder reveals AKAP11 as a risk gene shared with schizophrenia. Nature Genetics (10.1038/s41588-022-01034-x)
• Chambers, T. et al. 2022. Genetic common variants associated with cerebellar volume and their overlap with mental disorders: a study on 33,265 individuals from the UK-Biobank. Molecular Psychiatry 27 , pp.2282-2290. (10.1038/s41380-022-01443-8)
• Singh, T. et al., 2022. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604 , pp.509-516. (10.1038/s41586-022-04556-w)
• Trubetskoy, V. et al., 2022. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. Nature 604 , pp.502-508. (10.1038/s41586-022-04434-5)
• Okhuijsen-Pfeifer, C. et al., 2022. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry 12 145. (10.1038/s41398-022-01884-3)
• Alamian, G. et al., 2022. Altered brain criticality in schizophrenia: new insights from magnetoencephalography. Frontiers in Neural Circuits 16 630621. (10.3389/fncir.2022.630621)
• Lynham, A. J. , Jones, I. R. and Walters, J. T. R. 2022. Web-based cognitive testing in psychiatric research: validation and usability study. Journal of Medical Internet Research 24 (2) e28233. (10.2196/28233)
• Mullins, N. et al., 2022. Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders and known risk factors. Biological Psychiatry 91 (3), pp.313-327. (10.1016/j.biopsych.2021.05.029)
• Warne, N. et al. 2022. Collecting genetic samples and linked mental health data from adolescents in schools: protocol co-production and a mixed-methods pilot of feasibility and acceptability. BMJ Open 12 (2) e049283. (10.1136/bmjopen-2021-049283)
• Davies, M. R. et al., 2022. Comparison of symptom-based versus self-reported diagnostic measures of anxiety and depression disorders in the GLAD and COPING cohorts. Journal of Anxiety Disorders 85 102491. (10.1016/j.janxdis.2021.102491)
• Jones, H. J. et al., 2022. Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychological Medicine 52 (1), pp.132-139. (10.1017/S0033291720001798)
• Lynham, A. J. et al. 2022. A meta-analysis comparing cognitive function across the mood/psychosis diagnostic spectrum. Psychological Medicine 52 (2), pp.323-331. (10.1017/S0033291720002020)
• Vassos, E. et al., 2022. Lack of support for the genes by early environment interaction hypothesis in the pathogenesis of schizophrenia. Schizophrenia Bulletin 48 (1), pp.20-26. (10.1093/schbul/sbab052)
• Pardinas, A. et al. 2022. Interaction testing and polygenic risk scoring to estimate the contribution of common genetic variants to treatment resistance in schizophrenia. JAMA Psychiatry 79 (3), pp.260-269. (10.1001/jamapsychiatry.2021.3799)

2021

• Pardinas, A. F. , Owen, M. J. and Walters, J. T. 2021. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron 109 (24), pp.3914-3929. (10.1016/j.neuron.2021.09.011)
• Millgate, E. et al., 2021. A cross sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. BMJ Open 11 e054160. (10.1136/bmjopen-2021-054160)
• Thompson, K. N. et al., 2021. Age and sex-related variability in the presentation of generalized anxiety and depression symptoms. Depression and Anxiety 38 (10), pp.1054-1065. (10.1002/da.23213)
• Dennison, C. et al. 2021. Risk factors, clinical features, and polygenic risk scores in schizophrenia and schizoaffective disorder depressive-type. Schizophrenia Bulletin 47 (5), pp.1375-1384. (10.1093/schbul/sbab036)
• Jia, X. et al., 2021. Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder. Molecular Psychiatry 26 , pp.5239-5250. (10.1038/s41380-020-01006-9)
• Clifton, N. E. et al. 2021. Developmental profile of psychiatric risk associated with voltage-gated cation channel activity. Biological Psychiatry 90 (6)(10.1016/j.biopsych.2021.03.009)
• Rees, E. et al. 2021. Schizophrenia, autism spectrum disorders and developmental disorders share specific disruptive coding mutations. Nature Communications 12 5353. (10.1038/s41467-021-25532-4)
• Martin, J. et al. 2021. Examining sex differences in neurodevelopmental and psychiatric genetic risk in anxiety and depression. PLoS ONE 16 (9) e0248254. (10.1371/journal.pone.0248254)
• Cleynen, I. et al., 2021. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry , pp.4496-4510. (10.1038/s41380-020-0654-3)
• Legge, S. et al. 2021. Associations between schizophrenia polygenic liability, symptom dimensions, and cognitive ability in schizophrenia. JAMA Psychiatry 78 (10), pp.1143-1151. (10.1001/jamapsychiatry.2021.1961)
• Greene, M. C. et al., 2021. The epidemiology of psychiatric disorders in Africa: a scoping review. The Lancet Psychiatry 8 (8), pp.717-731. (10.1016/S2215-0366(21)00009-2)
• Clifton, N. E. et al. 2021. Genetic association of FMRP targets with psychiatric disorders. Molecular Psychiatry 26 , pp.2977-2990. (10.1038/s41380-020-00912-2)
• Hubbard, L. et al. 2021. Rare copy number variations are associated with poorer cognition in schizophrenia. Biological Psychiatry 90 (1), pp.28-34. (10.1016/j.biopsych.2020.11.025)
• Byrne, E. et al., 2021. Conditional GWAS analysis to identify disorder-specific SNPs for psychiatric disorders. Molecular Psychiatry 26 , pp.2070-2081. (10.1038/s41380-020-0705-9)
• Hall, L. S. et al. 2021. Cis-effects on gene expression in the human prenatal brain associated with genetic risk for neuropsychiatric disorders. Molecular Psychiatry 26 , pp.2082-2088. (10.1038/s41380-020-0743-3)
• Mullins, N. et al., 2021. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics 53 , pp.817-829. (10.1038/s41588-021-00857-4)
• Peterson, R. E. et al., 2021. Genome-wide analyses of smoking behaviors in schizophrenia: findings from the Psychiatric Genomics Consortium. Journal of Psychiatric Research 137 , pp.215-225. (10.1016/j.jpsychires.2021.02.027)
• Enache, D. et al., 2021. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophrenia Research 230 , pp.1-8. (10.1016/j.schres.2020.12.020)
• Willcocks, I. et al. 2021. Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. Frontiers in Pharmacology 12 658734. (10.3389/fphar.2021.658734)
• Konte, B. et al., 2021. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry. Translational Psychiatry 11 214. (10.1038/s41398-021-01322-w)
• Egerton, A. et al., 2021. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophrenia Bulletin 47 (2), pp.505-516. (10.1093/schbul/sbaa128)
• Dennison, C. A. et al. 2021. Association of genetic liability for psychiatric disorders with accelerometer-assessed physical activity in the UK Biobank. PLoS ONE 16 (3) e0249189. (10.1371/journal.pone.0249189)
• Chauquet, S. et al., 2021. Investigating the potential effects of antihypertensive medication on psychiatric disorders: a mendelian randomisation study. JAMA Psychiatry 78 (6), pp.623-631. (10.1001/jamapsychiatry.2021.0005)
• Gascoyne, L. E. et al., 2021. Motor-related oscillatory activity in schizophrenia according to phase of illness and clinical symptom severity. NeuroImage: Clinical 29 102524. (10.1016/j.nicl.2020.102524)

2020

• Kendall, K. M. et al. 2020. Impact of schizophrenia genetic liability on the association between schizophrenia and physical illness: a data linkage study. BJPsych Open 6 (6) e139. (10.1192/bjo.2020.42)
• Alamian, G. et al., 2020. Patient, interrupted: MEG oscillation dynamics reveal temporal dysconnectivity in schizophrenia. NeuroImage: Clinical 28 102485. (10.1016/j.nicl.2020.102485)
• Legge, S. E. et al. 2020. The Duffy-null genotype and risk of infection. Human Molecular Genetics 29 (20), pp.3341-3349. (10.1093/hmg/ddaa208)
• Jones, H. J. et al., 2020. A Mendelian randomization study of the causal association between anxiety phenotypes and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 183 (6), pp.360-369. (10.1002/ajmg.b.32808)
• Lee, S. C. et al., 2020. Area deprivation, urbanicity, severe mental illness and social drift — a population-based linkage study using routinely collected primary and secondary care data. Schizophrenia Research 220 , pp.130-140. (10.1016/j.schres.2020.03.044)
• Legge, S. et al. 2020. Clinical indicators of treatment-resistant psychosis. British Journal of Psychiatry 216 (5), pp.259-266. (10.1192/bjp.2019.120)
• Foley, C. et al., 2020. Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study. British Journal of Psychiatry 216 (5), pp.275-279. (10.1192/bjp.2019.262)
• Richards, A. et al. 2020. The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46 (2), pp.-. (10.1093/schbul/sbz061)
• Dennison, C. A. et al. 2020. Genome-wide association studies in schizophrenia: Recent advances, challenges and future perspective. Schizophrenia Research 217 , pp.4-12. (10.1016/j.schres.2019.10.048)
• Rees, E. et al. 2020. De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. Nature Neuroscience 23 (2), pp.179-184. (10.1038/s41593-019-0565-2)
• Hall, L. S. et al. 2020. A transcriptome-wide association study implicates specific pre- and post-synaptic abnormalities in schizophrenia. Human Molecular Genetics 29 (1), pp.159-167. (10.1093/hmg/ddz253)

2019

• Davies, M. R. et al., 2019. The Genetic Links to Anxiety and Depression (GLAD) study: online recruitment into the largest recontactable study of depression and anxiety. Behaviour Research and Therapy 123 103503. (10.1016/j.brat.2019.103503)
• Legge, S. E. et al. 2019. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. JAMA Psychiatry 76 (12), pp.1256-1265. (10.1001/jamapsychiatry.2019.2508)
• Lee, P. H. et al., 2019. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179 (7), pp.1469-1482.e11. (10.1016/j.cell.2019.11.020)
• Escott-Price, V. et al. 2019. Polygenic risk for schizophrenia and season of birth within the UK Biobank cohort. Psychological Medicine 49 (15), pp.2499-2504. (10.1017/S0033291718000454)
• D'Ambrosio, E. et al., 2019. The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research: Neuroimaging 291 , pp.34-41. (10.1016/j.pscychresns.2019.07.005)
• Escott-Price, V. et al. 2019. The relationship between common variant schizophrenia liability and number of offspring in the UK Biobank. American Journal of Psychiatry 176 (8), pp.661-666. (10.1176/appi.ajp.2018.18020140)
• Mulllins, N. et al., 2019. GWAS of suicide attempt in psychiatric disorders identifies association with major depression polygenic risk scores. American Journal of Psychiatry 176 (8), pp.651-660. (10.1176/appi.ajp.2019.18080957)
• Shaw, A. D. et al. 2019. Oscillatory, computational and behavioural evidence for impaired GABAergic inhibition in schizophrenia. Schizophrenia Bulletin 46 (2), pp.345-353. (10.1093/schbul/sbz066)
• Pardinas, A. F. et al. 2019. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. American Journal of Psychiatry 176 (6), pp.477-486. (10.1176/appi.ajp.2019.18050589)
• Pettersson, E. et al., 2019. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. Psychological Medicine 49 (7), pp.1166-1173. (10.1017/S0033291718002039)
• Kendall, K. M. et al. 2019. Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank. British Journal of Psychiatry 214 (05), pp.297-304. (10.1192/bjp.2018.301)
• Huckins, L. M. et al., 2019. Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. Nature Genetics 51 , pp.659-674. (10.1038/s41588-019-0364-4)
• Kendall, K. M. et al. 2019. Association of rare copy number variants with risk of depression. JAMA Psychiatry 76 (8), pp.818-825. (10.1001/jamapsychiatry.2019.0566)
• Gorman, K. M. et al., 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104 (5), pp.948-956. (10.1016/j.ajhg.2019.03.005)
• Harold, D. et al., 2019. Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 180 (3), pp.223-231. (10.1002/ajmg.b.32716)
• Rees, E. et al. 2019. Targeted sequencing of 10,198 samples confirms abnormalities in neuronal activity and implicates voltage-gated sodium channels in schizophrenia pathogenesis. Biological Psychiatry 85 (7), pp.554-562. (10.1016/j.biopsych.2018.08.022)
• Legge, S. E. et al. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24 , pp.328-337. (10.1038/s41380-018-0335-7)
• Legge, S. E. and Walters, J. T. 2019. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics 20 (4), pp.279-290. (10.2217/pgs-2018-0188)
• Crawford, K. et al. 2019. Medical consequences of pathogenic CNVs in adults: Analysis of the UK Biobank. Journal of Medical Genetics 56 , pp.131-138. (10.1136/jmedgenet-2018-105477)
• Clifton, N. E. et al. 2019. Dynamic expression of genes associated with schizophrenia and bipolar disorder across development. Translational Psychiatry 9 74. (10.1038/s41398-019-0405-x)
• Escott-Price, V. et al. 2019. Genetic liability to schizophrenia is negatively associated with educational attainment in UK Biobank. Journal of Molecular Psychiatry , pp.-. (10.1038/s41380-018-0328-6)
• Vivian-Griffiths, T. et al. 2019. Predictive modeling of schizophrenia from genomic data: Comparison of polygenic risk score with kernel support vector machines approach. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 180 (1), pp.80-85. (10.1002/ajmg.b.32705)

2018

• Li, M. et al., 2018. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. Science 362 (6420) eaat7615. (10.1126/science.aat7615)
• Dahoun, T. et al., 2018. The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Human Molecular Genetics 27 (20), pp.3498-3506. (10.1093/hmg/ddy242)
• John, A. et al. 2018. Premature mortality among people with severe mental illness - new evidence from linked primary care data. Schizophrenia Research 199 , pp.154-162. (10.1016/j.schres.2018.04.009)
• Jones, H. J. et al., 2018. Investigating the genetic architecture of general and specific psychopathology in adolescence. Translational Psychiatry 8 (1) 145. (10.1038/s41398-018-0204-9)
• Skene, N. G. et al., 2018. Genetic identification of brain cell types underlying schizophrenia. Nature Genetics 50 , pp.825-833. (10.1038/s41588-018-0129-5)
• Anttila, V. et al., 2018. Analysis of shared heritability in common disorders of the brain. Science 360 (6395) eaap8757. (10.1126/science.aap8757)
• Ruderfer, D. M. et al., 2018. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173 (7), pp.1705-1715.e16. (10.1016/j.cell.2018.05.046)
• Leonenko, G. et al. 2018. A data-driven investigation of relationships between bipolar psychotic symptoms and schizophrenia genome-wide significant genetic loci. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 177 (4), pp.468-475. (10.1002/ajmg.b.32635)
• Blokland, G. A. et al., 2018. The genetics of endophenotypes of neurofunction to understand schizophrenia (GENUS) consortium: a collaborative cognitive and neuroimaging genetics project. Schizophrenia Research 195 , pp.306-317. (10.1016/j.schres.2017.09.024)
• Reddaway, J. et al. 2018. Genomic and imaging biomarkers in schizophrenia. In: Current Topics in Behavioral Neurosciences. Berlin and Heidelberg: Springer. , pp.325-352. (10.1007/7854_2018_52)
• Lynham, A. et al. 2018. Examining cognition across the bipolar / schizophrenia diagnostic spectrum. Journal of Psychiatry and Neuroscience 43 (3) 170076. (10.1503/jpn.170076)
• Pardinas, A. F. et al. 2018. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics 50 , pp.381-389. (10.1038/s41588-018-0059-2)
• Ellis, N. C. et al., 2018. Medical student attitudes to mental health and psychiatry: the use of a patient-experience short film. The British Student Doctor Journal 2 (1), pp.3-10. (10.18573/bsdj.37)
• Allardyce, J. et al. 2018. Association between schizophrenia-related polygenic liability and the occurrence and level of mood-incongruent psychotic symptoms in bipolar disorder. JAMA Psychiatry 75 (1), pp.28-35. (10.1001/jamapsychiatry.2017.3485)

2017

• Cosgrove, D. et al., 2017. Cognitive characterization of schizophrenia risk variants involved in synaptic transmission: evidence of CACNA1C's role in working memory. Neuropsychopharmacology 42 , pp.2612-2622. (10.1038/npp.2017.123)
• Leonenko, G. et al. 2017. Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 174 (7), pp.724-731. (10.1002/ajmg.b.32560)
• Legge, S. E. et al. 2017. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry 22 , pp.1502-1508. (10.1038/mp.2016.97)
• Chawner, S. et al. 2017. Childhood cognitive development in 22q11.2 deletion syndrome: case–control study. British Journal of Psychiatry 211 (4), pp.223-230. (10.1192/bjp.bp.116.195651)
• Singh, T. et al., 2017. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nature Genetics 49 , pp.1167-1173. (10.1038/ng.3903)
• Kendall, K. M. et al. 2017. Cognitive performance among carriers of pathogenic copy number variants: analysis of 152,000 UK Biobank subjects. Biological Psychiatry 82 (2), pp.P103-110. (10.1016/j.biopsych.2016.08.014)
• Allardyce, J. et al. 2017. Psychosis and the level of mood incongruence in bipolar disorder are related to genetic liability for schizophrenia. bioRxiv
• Blokland, G. A. M. et al., 2017. Heritability of neuropsychological measures in Schizophrenia and non-psychiatric populations: a systematic review and meta-analysis. Schizophrenia Bulletin 43 (4), pp.788-800. (10.1093/schbul/sbw146)
• Hendricks, A. E. et al., 2017. Rare variant analysis of human and rodent obesity genes in individuals with severe childhood obesity. Scientific Reports 7 4394. (10.1038/s41598-017-03054-8)
• Hassoulas, A. et al. 2017. A case-based medical curriculum for the 21st century: The use of innovative approaches in designing and developing a case on mental health. Medical Teacher 39 (5), pp.505-511. (10.1080/0142159X.2017.1296564)
• Howes, O. D. et al., 2017. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. The American Journal of Psychiatry 174 (3), pp.216-229. (10.1176/appi.ajp.2016.16050503)
• Clifton, N. E. et al. 2017. Schizophrenia copy number variants and associative learning. Molecular Psychiatry 22 (2), pp.178-182. (10.1038/mp.2016.227)
• Marshall, C. R. et al., 2017. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics 49 , pp.27-35. (10.1038/ng.3725)

2016

• Whitton, L. et al., 2016. Cognitive analysis of schizophrenia risk genes that function as epigenetic regulators of gene expression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171 (8), pp.1170-1179. (10.1002/ajmg.b.32503)
• Rees, E. et al. 2016. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 73 (9), pp.963-969. (10.1001/jamapsychiatry.2016.1831)
• Tansey, K. E. et al. 2016. Common alleles contribute to schizophrenia in CNV carriers. Molecular Psychiatry 21 , pp.1085-1089. (10.1038/mp.2015.143)
• Pardinas, A. et al. 2016. Common schizophrenia alleles are enriched in mutation-intolerant genes and maintained by background selection. bioRxiv (10.1101/068593)
• Legge, S. et al. 2016. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophrenia Research 174 , pp.113-119. (10.1016/j.schres.2016.05.002)
• Han, J. et al. 2016. Gender differences in CNV burden do not confound schizophrenia CNV associations. Scientific Reports 6 25986. (10.1038/srep25986)
• Isles, A. R. et al. 2016. Parental origin of interstitial duplications at 15q11.2-q13.3 in schizophrenia and neurodevelopmental disorders. PLoS Genetics 12 (5) e1005993. (10.1371/journal.pgen.1005993)
• Thompson, J. V. et al., 2016. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Journal of Psychopharmacology 30 (5), pp.436-443. (10.1177/0269881116632376)
• Walters, J. T. R. and Owen, M. J. 2016. Genome-wide significant associations for cannabis dependence severity. JAMA Psychiatry 73 (5), pp.443-444. (10.1001/jamapsychiatry.2016.0046)
• Singh, T. et al., 2016. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nature Neuroscience 19 (4), pp.571-577. (10.1038/nn.4267)
• Carroll, L. S. et al., 2016. Mutation screening of SCN2A in schizophrenia and identification of a novel loss-of-function mutation. Psychiatric Genetics 26 (2), pp.60-65. (10.1097/YPG.0000000000000110)
• Franke, B. et al., 2016. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience 19 (3), pp.420-431. (10.1038/nn.4228)
• Jones, H. J. et al., 2016. Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. JAMA Psychiatry 73 (3), pp.221-228. (10.1001/jamapsychiatry.2015.3058)
• Richards, A. et al. 2016. Exome arrays capture polygenic rare variant contributions to schizophrenia. Human Molecular Genetics 25 (5), pp.1001-1007. (10.1093/hmg/ddv620)
• Hubbard, L. et al. 2016. Evidence of common genetic overlap between schizophrenia and cognition. Schizophrenia Bulletin 42 (3), pp.832-842. (10.1093/schbul/sbv168)

2015

• Tansey, K. E. et al. 2015. Common alleles contribute to schizophrenia in CNV carriers [Erratum]. Molecular Psychiatry 21 1153. (10.1038/mp.2015.170)
• Walter, K. et al., 2015. The UK10K project identifies rare variants in health and disease. Nature 526 , pp.82-90. (10.1038/nature14962)
• Huang, J. et al., 2015. Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. Nature Communications 6 8111. (10.1038/ncomms9111)
• Lloyd, K. et al., 2015. A national population-based e-cohort of people with psychosis (PsyCymru) linking prospectively ascertained phenotypically rich and genetic data to routinely collected records: Overview, recruitment and linkage. Schizophrenia Research 166 (1-3), pp.131-6. (10.1016/j.schres.2015.05.036)
• Loohuis, L. M. O. et al., 2015. Genome-wide burden of deleterious coding variants increased in schizophrenia. Nature Communications 6 7501. (10.1038/ncomms8501)
• Pocklington, A. et al. 2015. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron 86 (5), pp.1203-1214. (10.1016/j.neuron.2015.04.022)
• Kirov, G. , Rees, E. and Walters, J. T. R. 2015. What a psychiatrist needs to know about copy number variants. BJPscyh Advances 21 (3), pp.157-163. (10.1192/apt.bp.113.012039)
• Collier, D. et al., 2015. How can pharmacogenomics biomarkers be translated into patient benefit [Conference Abstract]. European Psychiatry 30 (Suppl1), pp.94-94. (10.1016/S0924-9338(15)30078-X)
• Vivian-Griffiths, T. et al. 2015. Utilising machine-learning algorithms to uncover complex genetic interactions in schizophrenia [Conference Abstract]. Human Heredity 79 (1), pp.48-48. A46. (10.1159/000381109)
• Taylor, P. N. et al. 2015. Whole-genome sequence-based analysis of thyroid function. Nature Communications 6 5681. (10.1038/ncomms6681)
• Walters, J. T. R. 2015. Treatment resistant schizophrenia: precision genetics or more of the same? [Conference Abstract]. Schizophrenia Bulletin 41 (Suppl1), pp.S215-S215. (10.1093/schbul/sbv010)
• Green, E. K. et al., 2015. Copy number variation in bipolar disorder. Molecular Psychiatry 21 (1), pp.89-93. (10.1038/mp.2014.174)
• Rees, E. et al. 2015. Analysis of exome sequence in 604 trios for recessive genotypes in schizophrenia. Translational Psychiatry 5 (7) e607. (10.1038/tp.2015.99)

2014

• Gusev, A. et al., 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. American Journal of Human Genetics 95 (5), pp.535-552. (10.1016/j.ajhg.2014.10.004)
• Timpson, N. J. et al., 2014. A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nature Communications 5 4871. (10.1038/ncomms5871)
• Szatkiewicz, J. P. et al., 2014. Copy number variation in schizophrenia in Sweden. Molecular Psychiatry 19 (7), pp.762-773. (10.1038/mp.2014.40)
• Ripke, S. et al., 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (7510), pp.421-427. (10.1038/nature13595)
• Rees, E. et al. 2014. Authors' reply [Letter]. British Journal of Psychiatry 205 (1), pp.78. (10.1192/bjp.205.1.78)
• Morris, D. W. et al., 2014. An inherited duplication at the gene p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis. Human Molecular Genetics 23 (12), pp.3316-3326. (10.1093/hmg/ddu025)
• Rees, E. et al. 2014. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Human Molecular Genetics 23 (6), pp.1669-1676. (10.1093/hmg/ddt540)
• Monks, S. et al., 2014. Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome. Schizophrenia Research 153 (1-3), pp.231-236. (10.1016/j.schres.2014.01.020)
• Rees, E. et al. 2014. Analysis of copy number variations at 15 schizophrenia-associated loci. British Journal of Psychiatry 204 (2), pp.108-114. (10.1192/bjp.bp.113.131052)

2013

• Schmechtig, A. et al., 2013. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational Psychiatry 3 (12) e334. (10.1038/tp.2013.109)
• Rees, E. et al. 2013. Evidence that duplications of 22q11.2 protect against schizophrenia. Molecular Psychiatry n/a (10.1038/mp.2013.156)
• Ripke, S. et al., 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics 45 (10), pp.1150-1159. (10.1038/ng.2742)
• Walters, J. T. R. et al. 2013. The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. American Journal of Psychiatry 170 (8), pp.877-885. (10.1176/appi.ajp.2013.12020226)
• Hamshere, M. L. et al. 2013. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Molecular Psychiatry 18 (6), pp.708-712. (10.1038/mp.2012.67)
• Donohoe, G. et al., 2013. Neuropsychological effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253. Genes, Brain and Behavior 12 (2), pp.203-209. (10.1111/gbb.12016)
• Kirov, G. et al. 2013. The penetrance of copy number variations for schizophrenia and developmental delay. Biological Psychiatry 75 (5), pp.378-385. (10.1016/j.biopsych.2013.07.022)
• Niarchou, M. et al. 2013. Defective processing speed and nonclinical psychotic experiences in children: longitudinal analyses in a large birth cohort. American Journal of Psychiatry 170 (5), pp.550-557. (10.1176/appi.ajp.2012.12060792)

2012

• O'Donovan, M. C. et al. 2012. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biological psychiatry 72 (8), pp.620-628. (10.1016/j.biopsych.2012.05.035)
• Koychev, I. et al., 2012. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. European Neuropsychopharmacology 22 (7), pp.469-481. (10.1016/j.euroneuro.2011.10.005)
• Economou, A. et al. 2012. The health informatics cohort enhancement project (HICE): using routinely collected primary care data to identify people with a lifetime diagnosis of psychotic disorder. BMC Research Notes 5 (1), pp.95-100. (10.1186/1756-0500-5-95)

2011

• Stergiakouli, E. et al., 2011. Steroid sulfatase is a potential modifier of cognition in attention deficit hyperactivity disorder. Genes Brain and Behavior 10 (3), pp.334-344. (10.1111/j.1601-183x.2010.00672.x)
• Altınbaş, K. et al., 2011. A survey of verbal and physical assaults towards psychiatrists in Turkey. International Journal of Social Psychiatry 57 (6), pp.631-636. (10.1177/0020764010382364)
• Carroll, L. S. et al. 2011. Mutation screening of the 3q29 microdeletion syndrome candidate genes DLG1 and PAK2 in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156 (7), pp.844-849. (10.1002/ajmg.b.31231)
• Donohoe, G. et al., 2011. A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRGN rs12807809 [Letter]. Schizophrenia Research 125 (2-3), pp.304-306. (10.1016/j.schres.2010.10.019)
• Dwyer, S. L. et al. 2011. Investigation of rare non-synonymous variants at ABCA13 in schizophrenia and bipolar disorder [letter]. Molecular Psychiatry 16 (8), pp.790-791. (10.1038/mp.2011.2)

2010

• Walters, J. T. R. et al. 2010. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Archives of General Psychiatry 67 (7), pp.692-700. (10.1001/archgenpsychiatry.2010.81)

2009

• Donohoe, G. et al., 2009. Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Archives of General Psychiatry 66 (10), pp.1045-1054. (10.1001/archgenpsychiatry.2009.139)
• Smith, D. J. et al. 2009. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatrica Scandinavica 119 (4), pp.325-329. (10.1111/j.1600-0447.2008.01324.x)

2008

• Craddock, N. J. et al. 2008. Authors' reply. The British Journal of Psychiatry 193 (6), pp.517. (10.1192/bjp.193.6.517)
• Craddock, N. J. et al. 2008. Wake-up call for British psychiatry. British Journal of Psychiatry 193 (1), pp.6-9. (10.1192/bjp.bp.108.053561)
• Craddock, N. J. et al. 2008. Wake up call: Response from authors [eLetter]. British Journal of Psychiatry
• Robertson Blackmore, E. et al., 2008. Is the perimenopause a time of increased risk of recurrence in women with a history of bipolar affective postpartum psychosis? A case series. Archives of Women's Mental Health 11 (1), pp.75-78. (10.1007/s00737-008-0215-2)
• Smith, D. J. et al. 2008. Differences in depressive symptom profile between males and females. Journal of Affective Disorders 108 (3), pp.279-284. (10.1016/j.jad.2007.10.001)
• Walters, J. T. R. and Jones, I. R. 2008. Clinical questions and uncertainty - prolactin measurement in patients with schizophrenia and bipolar disorder. Journal of Psychopharmacology 22 (Supp 2), pp.82-89. (10.1177/0269881107086516)

2007

• Walters, J. T. R. and Owen, M. J. 2007. Endophenotypes in psychiatric genetics [Guest Editorial]. Molecular Psychiatry 12 (10), pp.886-890. (10.1038/sj.mp.4002068)
• Smith, D. J. and Walters, J. T. R. 2007. Bipolarity is important during treatment with antidepressants [Comment]. British Medical Journal (BMJ) 334 (7589), pp.327-327. (10.1136/bmj.39121.846667.1F)
• Walters, J. T. R. , Bisson, J. I. and Shepherd, J. P. 2007. Predicting post-traumatic stress disorder: validation of the Trauma Screening Questionnaire in victims of assault. Psychological medicine 37 (1), pp.143-150. (10.1017/S0033291706008658)

2004

• Ohlsen, R. I. et al., 2004. Clinical effectiveness in first-episode patients. European Neuropsychopharmacology 14 (4), pp.S445-S451.
• O'Toole, M. S. et al., 2004. Treating first episode psychosis - the service users' perspective: a focus group evaluation. Journal of Psychiatric and Mental Health Nursing 11 (3), pp.319-326. (10.1111/j.1365-2850.2004.00730.x)

2003

• Taylor, T. et al., 2003. Safety of Quetiapine During Pregnancy. American Journal of Psychiatry 160 (3), pp.588-589. (10.1176/appi.ajp.160.3.588-a)

1996

• Toh, S. K. C. , Walters, J. T. R. and Johnson, C. D. 1996. APACHE-O - A new predictor of severity in acute pancreatitis.. Gastroenterology 110 (4), pp.A437-A437.